Catalyst
Slingshot members are tracking this event:
FDA decision for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide anticipated in November 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SNY | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 21, 2016
Occurred Source:
http://mediaroom.sanofi.com/sanofi-receives-fda-approval-of-soliqua-10033-for-the-treatment-of-adults-with-type-2-diabetes/
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Nda, Glargine, Lixisenatide, Basal Insulin Glargine, Glp-1 Receptor, Type 2 Diabetes
